No open-market selling at Neuphoria Therapeutics Inc. in the past year, which is unusual. Instead one insiders picked up about $3.3 million worth of NEUP.
Biggest single buyer: Lynx1 Capital Management LP, 10% Owner, with roughly $3.3 million.
Big money check: 22 institutions held NEUP as of Q2 2026, and more funds bought than sold. Quarter by quarter: No open-market insider buying or selling in the last full quarter. Insiders bought in 1 of the last 7 full quarters.
| Filed | Insider | Role | Type | Shares | Price | Value | Source |
|---|---|---|---|---|---|---|---|
| Oct 23, 2025 | Lynx1 Capital Management LP | 10% Owner | Buy | 639,110 | $5.14 | $3.3M | SEC |
In the last 12 months Neuphoria Therapeutics Inc. insiders made open-market purchases worth about $3.3 million and sales worth about $0. Data comes from SEC Form 4 filings, updated every 30 minutes on CapitalSnitch.
The most recent open-market insider trade in NEUP was filed on 2025-10-23.
22 investment managers reported holding NEUP in SEC Form 13F filings for Q2 2026.
No congressional trades in NEUP were reported in the past two years. The full list is free on CapitalSnitch.
Public-record data for research and education, not investment advice. Insider sales are often pre-planned (10b5-1). Congress data: Data derived from public disclosures filed under the Ethics in Government Act and the STOCK Act, republished free for public transparency and news reporting. Disclosures may lag the trade by 45 days or more and show amounts only as ranges. This data may not be used for credit rating, loan underwriting, solicitation of money (political, charitable or other), direct-mail or commercial targeting (5 U.S.C. 13107).